Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Pregnant or lactating women. Women of childbearing potential are required to have a negative pregnancy test
• •Women of childbearing potential and fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study until at least 12 weeks after the last weekly hA20 infusion.
• •Rituximab resistant, defined as having progressed during or within 6 months of rituximab treatment.
• •Excessive toxicity to rituximab (NCI CTC Grade 3 or 4) or known to be HACA positive
• •Prior radioimmunotherapy, including Zevalin or Bexxar,
• •Prior therapy with other human or humanized monoclonal antibodies, unless HAHA tested and negative
• •Primary CNS lymphoma, HIV lymphoma or transformed lymphoma, or presence of symptomatic CNS metastases or carcinomatous meningitis.
• •Bulky disease by CT, defined as any single mass \>10 cm in its greatest diameter
• •Pleural effusion with positive cytology for lymphoma Known to be HIV positive, or hepatitis B or C positive
• •Known autoimmune disease or presence of autoimmune phenomena.
• •Evidence of infection or requiring antibiotics within 5 days.
• •Corticosteroid use within 2 weeks
• •Prior malignancy with less than a 5-year disease-free interval, excluding nonmelanoma skin cancers and carcinoma in situ of the cervix.
• •Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of studyprocedures and follow-up examinations